Your browser doesn't support javascript.
Understanding the immunological landscape of England during SARS-CoV2 Omicron variant wave.
Shingleton, Joseph; Dyke, Steven; Herrick, Archie; Finnie, Thomas.
  • Shingleton J; UK Health Security Agency, PHAGE Joint Modelling Team, Salisbury, United Kingdom.
  • Dyke S; UK Health Security Agency, PHAGE Joint Modelling Team, Salisbury, United Kingdom.
  • Herrick A; UK Health Security Agency, PHAGE Joint Modelling Team, Salisbury, United Kingdom.
  • Finnie T; UK Health Security Agency, PHAGE Joint Modelling Team, Salisbury, United Kingdom.
PLoS One ; 17(10): e0264870, 2022.
Article in English | MEDLINE | ID: covidwho-2079669
ABSTRACT
Understanding the scale of the threat posed by SARS-CoV2 B.1.1.529, or Omicron, variant formed a key problem in public health in the early part of 2022. Early evidence indicated that the variant was more transmissible and less severe than previous variants. As the virus was expected to spread quickly through the population of England, it was important that some understanding of the immunological landscape of the country was developed. This paper attempts to estimate the number of people with good immunity to the Omicron variant, defined as either recent infection with two doses of vaccine, or two doses of vaccine with a recent booster dose. To achieve this, we use a process of iterative proportional fitting to estimate the cell values of a contingency table, using national immunisation records and real-time model infection estimates as marginal values. Our results indicate that, despite the increased risk of immune evasion with the Omicron variant, a high proportion of England's population had good immunity to the virus, particularly in older age groups. However, low rates of immunity in younger populations may allow endemic infection to persist for some time.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Aged / Humans Country/Region as subject: Europa Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2022 Document Type: Article Affiliation country: Journal.pone.0264870

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Aged / Humans Country/Region as subject: Europa Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2022 Document Type: Article Affiliation country: Journal.pone.0264870